Stock INKT MINK THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus MiNK Therapeutics, Inc.

Equities

INKT

US6036931029

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-06-07 pm EDT 		5-day change 1st Jan Change
0.9642 USD -1.61% Intraday chart for MiNK Therapeutics, Inc. -0.59% -9.88%
May. 22 MiNK Therapeutics, Inc. Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting CI
May. 14 Transcript : MiNK Therapeutics, Inc., Q1 2024 Earnings Call, May 14, 2024

Evolution of the average Target Price on MiNK Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

10c0c4.hcwjikzXyGvmUUEYIMdIZXfzpanuMJc5bNEx88fX9wI.yI5q436i8TORNgRWRa9lOj6Xk5vZCfZrGINBgJWElVjThkS5OrKOIZ8JcQ~3038936811c9b27cb19062605974b578

Analyst Recommendations on MiNK Therapeutics, Inc.

HC Wainwright Adjusts MiNK Therapeutics Price Target to $10 From $7, Maintains Buy Rating MT
Evercore ISI Adjusts MiNK Therapeutics' Price Target to $3 From $4, Keeps Outperform Rating MT
HC Wainwright Initiates MiNK Therapeutics at Buy, Sets Price Target at $7 MT
B. Riley Lowers MiNK Therapeutics' Price Target to $7 from $10, Keeps Buy Rating MT
B. Riley Lowers MiNK Therapeutics' Price Target to $10 from $24 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
B. Riley Starts MiNK Therapeutics at Buy with $24 PT, Notes 'Attractive' Valuation, Disruptive Potential of iNKT Platform MT
William Blair Initiates Coverage on MiNK Therapeutics With Outperform Rating MT
Evercore ISI Starts MiNK Therapeutics at Outperform With $30 Price Target MT
Baird Starts MiNK Therapeutics at Outperform With $26 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9642 USD
Average target price
8 USD
Spread / Average Target
+729.66%
High Price Target
9 USD
Spread / Highest target
+833.37%
Low Price Target
7 USD
Spread / Lowest Target
+625.95%

Consensus detail

Consensus revision (last 18 months)

Analysts covering MiNK Therapeutics, Inc.

HC Wainwright
Evercore ISI
B. Riley
Baird
William Blair & Co.

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. INKT Stock
  4. Consensus MiNK Therapeutics, Inc.